PURE Bioscience Reports 27% Revenue Growth but Net Loss of $464,000 for Quarter Ending October 31, 2025

PURE Bioscience, Inc. reported its financial results for the three months ending October 31, 2025, revealing a total revenue of $708,000, a 27% increase from $556,000 in the same period last year. The growth in revenue was primarily driven by increased product sales, particularly from its flagship product, PURE® Hard Surface, which accounted for $707,000 of net product sales, up from $389,000 in the prior year. The company recorded a gross profit of $450,000, resulting in a gross margin of 64%, compared to 58% in the previous year, attributed to the sale of higher-margin product configurations.

Despite the increase in revenue, PURE Bioscience reported a net loss of $464,000 for the quarter, an improvement from the $689,000 loss recorded in the same period last year. The company’s operating expenses decreased to $829,000 from $952,000, largely due to reduced selling, general, and administrative expenses, which fell from $881,000 to $743,000. This reduction was partially offset by an increase in research and development expenses, which rose to $86,000 from $71,000.

On the balance sheet, total assets increased to $1,186,000 as of October 31, 2025, up from $1,058,000 at the end of the previous fiscal year. Current liabilities surged to $3,159,000, primarily due to the addition of $2,104,000 in convertible notes payable to related parties. The company’s stockholders’ deficiency widened to $5,546,000 from $5,116,000, reflecting ongoing financial challenges and a history of recurring losses.

Operationally, PURE Bioscience continues to focus on expanding its market presence and product offerings. The company is actively pursuing partnerships for regulatory approvals to market its products outside the U.S. and is developing additional proprietary products. As of the latest reporting period, the company had a cash balance of $434,000, which is a slight increase from $334,000 at the end of July 2025. However, the company’s ability to continue as a going concern remains in question due to its history of losses and negative cash flows from operations.

Looking ahead, PURE Bioscience anticipates that its future capital requirements will depend on various factors, including product acceptance and demand, regulatory approvals, and the costs associated with product development. The company acknowledges the need for additional financing to sustain operations, which may involve issuing equity or incurring debt, both of which could lead to dilution for existing shareholders. The management remains cautious about the company's financial outlook, emphasizing the importance of generating positive cash flow from operations to ensure long-term viability.